EVERSANA and Intouch Group join forces

EVERSANA and Intouch Group join forces

EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, and Intouch Group, a full-service global agency network serving the pharmaceutical industry, have signed an agreement to incorporate Intouch’s industry-leading creative and media services, enterprise solutions, and data analytics into EVERSANA’s fully integrated commercialization services platform. Management says together, the combined companies – with more than 40 global locations, 5,500 employees worldwide, and millions of dollars invested in digital transformation, data and analytics – are poised to deliver full-scale commercialization to pharmaceutical companies globally.

“Partnerships of this magnitude change the trajectory of industries and this one is simply overdue,” says Jim Lang, CEO of EVERSANA. “At EVERSANA, we’ve spent recent years tearing down the silos of a broken life sciences industry to reinvent commercialization. Intouch shares our vision and hearty appetite for disruption. Together, we will engage the entire life sciences ecosystem in new and powerful ways. Who better than EVERSANA and Intouch to actually change the game and improve healthcare worldwide?”

“More than 20 years ago, I founded Intouch with a belief that there is no challenge too big to cure,” says Faruk Capan, CEO of Intouch Group. “With EVERSANA, our team takes a monumental step forward. Not only will we continue to ensure our clients’ brands are accessible, but now we’ll also use our leadership in promotion and digital engagement to improve every sector of product commercialization. The challenge may be great, but our tenacity and commitment to innovation is far greater.”

The leadership team says under the terms of the agreement, both companies and their clients will immediately benefit from access to the full array of digitally driven, patient-centric services designed to solve any global pricing, access, reimbursement, promotion, adherence, or product delivery challenge.

The Intouch agency network, including its nine affiliates (Intouch Solutions, Intouch Proto, Intouch Seven, Intouch International, Intouch Media, Intouch B2D, Intouch Analytics, Intouch Market Access, and Intouch Oxygen), are further strengthened by and will propel EVERSANA’s commercial services platform spanning the complete product life cycle. The agency will immediately work closely with EVERSANA’s agency, EVERSANA ENGAGE.

EVERSANA expects the acquisition of Intouch to be closed by the end of the year. Financial details will not be disclosed. Houlihan Lokey served as the exclusive financial advisor to Intouch Group.

In another advance for EVERSANA, the company in November announced its membership in the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), the region’s principal trade association for small to medium-sized companies in the pharmaceutical, biotech and medtech industries. EVERSANA joins a trusted network of more than 1,300 research-oriented organizations, many of which develop therapeutic solutions for rare diseases as well as cell and gene therapies, to continue to provide innovative patient-centric solutions throughout Europe.

According to Lang, “In partnership with EUCOPE experts, we will ensure the full scale of EVERSANA’s global commercialization services stands ready to support the rich pipeline of products in development in Europe and beyond.”

Already serving more than 40 European pharmaceutical and biotechnology clients, EVERSANA supports more than 500 life sciences companies globally. The company’s rapid international expansion now includes more than 25 global offices and Europe-based employees working in the United Kingdom, France, Germany, Switzerland, Spain, Ireland, Bulgaria, Poland, Italy and Croatia.